Quick Answer
Gel-One denials happen regularly, especially from commercial plans that prefer multi-injection alternatives. As a single-injection cross-linked hyaluronate product, Gel-One faces similar denial patterns to Monovisc and Durolane. However, with proper documentation and a focused appeal, many denials can be reversed.
Why Gel-One Injections Get Denied
Gel-One (cross-linked hyaluronate) is manufactured by Zimmer Biomet. It delivers the full viscosupplementation treatment in a single 3 mL injection, which is convenient for patients but draws additional scrutiny from insurers.
1. Medical Necessity Not Established
Your insurer found the submitted documentation insufficient to demonstrate that viscosupplementation is medically necessary. This typically means your medical records lacked clear evidence of OA severity, imaging findings, or detailed functional limitations.
2. Conservative Treatment Failure Not Documented
Insurers require at least 3 months of documented conservative treatment before approving HA injections. Your records need to show specific dates, treatments tried, and why each was inadequate. Vague documentation without specifics is the most common reason for this type of denial.
3. Insurer Prefers Multi-Injection Product
Like other single-injection HA products, Gel-One faces product-preference denials. Insurers may argue that a multi-injection product (such as Hyalgan or Supartz at a lower per-dose cost) should be tried first. Your appeal needs to explain why single-injection treatment is clinically appropriate for you.
4. Product Not on Formulary
Gel-One has a smaller market share than Synvisc-One or Monovisc, and some plans have not included it on their formulary. In these cases, a formulary exception is needed, which requires documenting why Gel-One is specifically necessary.
5. Prior Authorization Missing
Most commercial and Medicare Advantage plans require prior authorization for all HA products, including Gel-One. Treatment without PA approval results in denial.
Gel-One Availability Note
Gel-One is less widely used than some other HA products. If your provider specifically recommends Gel-One, ensure they document the clinical rationale clearly. If your insurer is unfamiliar with the product, providing the FDA approval information and clinical data may be necessary as part of your appeal.
Step-by-Step Appeal Process
Step 1: Review Your Denial Letter
Identify the specific denial reason. Determine whether it is a medical necessity issue, a product-preference issue, or a process issue (missing PA). Note the appeal deadline.
Step 2: Gather Supporting Documentation
- Imaging: Knee X-rays with clear documentation of osteoarthritis findings
- Conservative treatment records: PT notes with dates, medication records with drug names, dosages, and outcomes, cortisone records if applicable
- Functional assessment: Documented limitations in walking, stairs, sleep, daily activities
- Gel-One-specific justification: If the denial is product-specific, document why single-injection treatment is needed (mobility limitations, transportation barriers, compliance concerns) or why Gel-One specifically (prior success, physician preference based on clinical factors)
- Physician letter: Detailed letter of medical necessity addressing each denial reason
Step 3: Write Your Appeal Letter
Address each denial reason directly. For product-preference denials, emphasize the clinical rationale for single-injection treatment and any patient-specific factors. For medical necessity denials, focus on comprehensive documentation.
Step 4: Submit and Follow Up
Submit via the plan’s preferred channel. Confirm receipt within 5 business days. Follow up weekly. Request peer-to-peer review if available.
Step 5: External Review Options
If your internal appeal fails:
- Commercial plans: Independent external review through state insurance department
- Medicare Advantage: IRE review, then ALJ
- Original Medicare: Redetermination, then QIC reconsideration
Sample Appeal Letter Template
[Your Name] [Your Address] [City, State, ZIP] [Date]
[Insurance Company Name] [Appeals Department Address] [City, State, ZIP]
RE: Appeal of Denial — Gel-One (cross-linked hyaluronate) Injection Member ID: [Your Member ID] Claim Number: [Claim Number from Denial Letter] Date of Service: [Date of Injection] Patient: [Your Name, DOB]
Dear Appeals Committee:
I am writing to appeal the denial of coverage for Gel-One injection for my [left/right] knee osteoarthritis, denied on [denial date] for the stated reason: “[exact denial reason].”
Diagnosis: Osteoarthritis of the [left/right] knee (ICD-10: [M17.11 or M17.12]), confirmed by X-rays on [date] showing [findings].
Why Gel-One: Gel-One is an FDA-approved, single-injection cross-linked hyaluronate product. My physician prescribed Gel-One based on [prior success with this product / clinical suitability of the cross-linked formulation / need for single-injection treatment due to mobility or transportation limitations].
Conservative Treatment History:
- Physical therapy: [number] sessions from [start date] to [end date]. Result: [limited improvement].
- NSAIDs: [medication] [dosage] from [start date] to [end date]. Result: [inadequate relief].
- Cortisone injection: [date]. Provided [X weeks] of temporary relief.
- Activity modification: [describe changes].
Functional Impact: My knee pain significantly limits my ability to [specific activities].
I respectfully request reversal of this denial. Supporting documentation is enclosed.
Sincerely, [Your Signature] [Your Printed Name] [Phone Number]
Enclosures: Denial letter, medical records, imaging, physician letter, conservative treatment records
CPT and HCPCS Codes for Gel-One
| Code Type | Code | Description |
|---|---|---|
| HCPCS (Product) | J7326 | Gel-One, cross-linked hyaluronate, for intra-articular injection, per dose |
| CPT (Injection) | 20610 | Arthrocentesis, aspiration and/or injection of major joint (without ultrasound) |
| CPT (Injection w/ imaging) | 20611 | Arthrocentesis with ultrasound guidance |
| ICD-10 (Diagnosis) | M17.0 | Bilateral primary osteoarthritis of knee |
| ICD-10 (Diagnosis) | M17.11 | Primary osteoarthritis, right knee |
| ICD-10 (Diagnosis) | M17.12 | Primary osteoarthritis, left knee |
| Office Visit | 99213/99214 | Established patient office visit (if billed same day) |
Coding Note for Gel-One
Gel-One uses J7326, its product-specific HCPCS code. The single injection delivers 3 mL (30 mg cross-linked hyaluronate). Bill one unit of J7326 per treatment. Because Gel-One has a smaller market share, some payer systems may not recognize J7326 — verify before treatment.
Gel-One-Specific Coverage Facts
About Gel-One
- Manufacturer: Zimmer Biomet (originally Seikagaku Corporation, Japan)
- Active ingredient: Cross-linked hyaluronate
- Molecular weight: High (cross-linked)
- Injection schedule: Single injection (3 mL)
- FDA approved: Yes, for knee osteoarthritis
- Source: Avian-derived (rooster comb)
- Market position: Less widely prescribed than Synvisc-One or Monovisc but clinically comparable
Medicare Coverage
Original Medicare covers Gel-One under Part B for knee OA. Patient pays 20% coinsurance after the $257 deductible (2026). PA is generally not required under Original Medicare. Medicare Advantage plans may require PA.
Commercial Insurance Coverage
Coverage is more variable than for widely-used brands:
- Some plans do not include Gel-One on formulary due to lower market share
- Prior authorization required by most plans
- Product-preference denials may occur in favor of more established brands
- Formulary exceptions require clinical justification for why Gel-One is necessary
Common LCD Requirements
- Radiographic evidence of knee osteoarthritis
- Failure of conservative therapy for 3+ months
- 6-month minimum interval between treatments
- Coverage limited to knee joint
- All FDA-approved HA products covered equally under most LCDs
Tips to Prevent Future Denials
- Verify Gel-One is on your plan’s formulary before treatment. If not, start the formulary exception process early.
- Get prior authorization with J7326 specifically listed
- Document why Gel-One is appropriate for your situation in the medical record
- Ensure your provider’s billing system recognizes J7326 before the injection date
- Complete conservative treatment documentation with specific dates and outcomes
- Note avian allergy status since Gel-One is avian-derived
- Use correct ICD-10 codes: M17.11 (right knee), M17.12 (left knee), M17.0 (bilateral)
Frequently Asked Questions
How long does a Gel-One appeal take?
Internal appeals: about 30 days. Expedited: 72 hours. External review: additional 30-60 days. Total: 4-12 weeks.
What is the success rate for Gel-One appeals?
Similar to other single-injection HA products. Medical necessity denials with complete documentation have a 40-60% overturn rate. Product-preference or formulary denials are harder unless you have a specific clinical reason for needing Gel-One.
Can my doctor help with the appeal?
Yes, your doctor’s letter is essential. Have your physician explain the clinical rationale for choosing Gel-One and address each denial reason. Peer-to-peer review can be especially effective.
What if my second appeal is denied?
Request external review. Also consider whether switching to a different single-injection product (Synvisc-One, Monovisc) or a multi-injection product on your plan’s formulary is acceptable. Sometimes the fastest path to treatment is using the insurer’s preferred product.
Why might my provider recommend Gel-One over other single-injection options?
Physicians choose among single-injection HA products based on their clinical experience, the specific cross-linking technology, and patient response. Gel-One uses a unique cross-linking process developed by Seikagaku Corporation. Your provider may have experience with better outcomes using Gel-One for certain patient profiles.